



**HERA** HEALTH EMERGENCY  
PREPAREDNESS AND  
RESPONSE AUTHORITY

#HealthUnion

# **HERA Industry days**

## Health Emergency Preparedness and Response Authority

2 & 3 June 2025, Brussels

## Side session

**Driving innovation and collaboration for  
global health preparedness**



Cécile BILLAUX  
Head of Unit - DG INTPA G4



Pauline BEATTIE  
Head of Unit Operations and  
Scientific Adviser - EDCTP



Olufunke FALADE  
Presidential Initiative for  
Unlocking the Healthcare  
Value Chain (PVAC)



Karim BENDHAOU  
Head of Africa & Chair of Africa  
Committee – Merck Group



Jorge EMILIO OSORIO  
Chief Executive Officer –  
Vaxthera



VaxThera



A STRATEGIC PARTNER

**FOR GLOBAL  
HEALTH SECURITY AND REGIONAL  
MANUFACTURING**

A company by:



# LATIN AMERICA

650

MILLION

inhabitants in the region

4

VACCINE


producers (Argentina, Brazil, Mexico and Cuba)

0

COUNTRIES

have the capacity to produce all the vaccines in their expanded program of immunization

**Limited supply for growing demand**



## COLOMBIA



Great opportunity for vaccine development



Strategic location and stable government



Government and private sector stakeholders



# VaxThera



We are a Colombian biotech company that develops **products and services** to contribute to **health security** in **Colombia** and the region by positively impacting people's health through **prevention**

A company by:



# Founders



## Jorge E. Osorio - CEO

- More than 35 years of experience in vaccine research and development
- Director of the Global Health Institute at the University of Wisconsin-Madison
- Professor in the Department of Pathobiological Sciences. University of Wisconsin-Madison
- Creator of the Takeda Dengue Vaccine
- Co-founder of Inviragen, later acquired by Takeda
- Holds more than 30 patents and has published more than 170 scientific publications



## Juan P. Hernández – CSO

- More than 20 years of experience in molecular engineering
- Professor in the Department of Materials and Nanotechnology
- Director of the GHI One Health Colombian Institute at Universidad Nacional in Colombia
- Published more than 120 scientific articles, one textbook, and 2 patents




## Seguros SURA

- Privately-owned company with more than 75 years of experience in risk management and tendencies, including a wide portfolio of insurance solutions
- Presence in 7 countries, more than 21 thousand employees, and 17.5 million clients
- Has committed an initial investment of 120 million dollars to support VaxThera's capacities.



# Horizons of Growth







# RESEARCH PIPELINE FOR HUMAN HEALTH



## PHASES:



## VACCINES:

Vaccine design

In vitro studies

Preclinical

Clinical Lots

Phase I

Phase II

Phase III



## TECHNOLOGY:



## ALLIES:

● Universal Coronavirus/Mpox

● Mpox

● Highly pathogenic avian influenza

● Chikungunya

● Zika

● Yellow Fever

● Dengue

● Filoviruses

● Human Papiloma Virus

Viral vector

Live-Attenuated Virus

Viral vector & mRNA

Viral vector & mRNA

Viral vector & mRNA

Viral vector & mRNA

Live-Attenuated Virus

Viral vector & mRNA


Viral vector & mRNA



# VAXTHERA'S MANUFACTURING PLANT









# ALLIES FOR TECHNOLOGY TRANSFER




## ALLIES

- Quantoom Biosciences
- Univercells Technologies
- Baush Technologies
- MSD
- SK Bioscience
- Butantan
- Bharat Biotech
- FioCruz
- European Commission
- European Investment Bank
- Bancolombia
- Universidad Nacional de Colombia
- University of Wisconsin - Madison
- Minister of Health and Social Protection of Colombia
- National Health Institute of Colombia

## PORTFOLIO FOR TECHNOLOGY TRANSFER

- |                  |                  |
|------------------|------------------|
| • HPV-9          | • Rituximab      |
| • Cell influenza | • Adalimumab     |
| • Varicella      | • Trastuzumab    |
| • Shingles       | • Bevacizumab    |
| • MMR            | • Pembrolizumab  |
| • Pentavalent    | • Pegaspargase   |
| • Hexavalent     | • Tenecteplase   |
| • Rotavirus      | • Pegfilgrastim  |
|                  | • Erythropoietin |





# LATAM Challenges

- Financing:
  - Government vs Private Sector
- Regulatory Environment
  - Slow and inefficient processes
  - There is no unified regulatory strategy across the region
- Government Partnerships are complex
- Human Talent
- Chain supply

# Role of EC Bringing Three Continents Together



- Strengthening funding for R&D
- Regulatory Standards
  - Within countries in the region and across the region
- Facilitating Tech transfer opportunities
  - Leveraging terms that are favorable for everyone
- Training & Collaboration
- Innovation
  - To face global Health threats
  - Vaccine and biologicals Production



Cécile BILLAUX  
Head of Unit - DG INTPA G4



Pauline BEATTIE  
Head of Unit Operations and  
Scientific Adviser - EDCTP



Olufunke FALADE  
Presidential Initiative for  
Unlocking the Healthcare  
Value Chain (PVAC)



Karim BENDHAOU  
Head of Africa & Chair of Africa  
Committee – Merck Group



Jorge EMILIO OSORIO  
Chief Executive Officer –  
Vaxthera

# Thank you